A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of CDX-3379 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 24 Aug 2017
At a glance
- Drugs CDX-3379 (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- Sponsors Celldex Therapeutics
- 17 Aug 2017 Status changed from planning to not yet recruiting.
- 08 Aug 2017 According to a Koltan Pharmaceuticals media release, the company expects to initiate this study in the fourth quarter of 2017.
- 18 May 2016 According to a Koltan Pharmaceuticals media release, this trial is expected to start in the year 2016.